Top 20 High-Conviction Stocks from the Latest Schwab Equity Screen: Building a Diversified Long-Term Portfolio

Top 20 High-Conviction Stocks from the Latest Schwab Equity Screen: Building a Diversified Long-Term Portfolio (Part 1 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

Quick Snapshot: We screened a rich dataset of high-quality U.S. and select international stocks using CFRA Star Rankings (predominantly 4–5 Stars), Argus and LSEG “Buy” consensus, Morningstar ratings and Economic Moat assessments, Schwab Equity Ratings (SER), valuation multiples (PEG, P/E, P/S, P/B, P/CF), growth estimates, profitability metrics (ROE, margins), balance-sheet strength, multi-year total returns, and beta. From that universe we selected the 20 stocks we have the highest confidence in for a diversified, long-term (5–10+ year) portfolio.

Welcome to a deep-dive series that turns raw screening data into actionable portfolio construction thinking. The goal is not to chase the hottest momentum name or the cheapest deep-value trap. Instead, we seek a balanced collection of businesses that combine solid fundamentals, reasonable (or at least justifiable) valuations, acceptable risk profiles, and enough category diversification to weather different market regimes.

In this first installment we set the stage: explain the screen, define our four scoring dimensions (Confidence, Value, Safety, Timing), outline the full series structure, and begin the foundational analysis of what the data actually tells us about quality, risk, and relative strength. Subsequent parts will deliver the ranked list with individual rationales, sector deep-dives, portfolio construction notes, risk scenarios, and monitoring frameworks.

Classic perspective on why high-quality equities remain the core long-term wealth engine — a useful mindset before we dig into the numbers.

Understanding the Schwab Stock Screen Data

The CSV provided is a filtered universe of stocks that already cleared several quality gates. Nearly every name carries a CFRA Star Ranking of 4 or 5 Stars and an Argus 12-Month Rating of “BUY.” Most also show LSEG I/B/E/S Mean of “Buy.” Morningstar ratings range from 1 to 5 stars, with a meaningful subset enjoying “Wide” Economic Moats. Schwab Equity Ratings (SER) span A through F, with percentile rankings that help us see relative attractiveness within the broader Schwab coverage universe of roughly 3,000 U.S.-headquartered names.

Key quantitative columns include:

• Valuation: Price/Earnings (multiple horizons), PEG (TTM), Price/Sales, Price/Book, Price/Cash Flow
• Growth: Estimated EPS growth (current year, next year, long-term 3–5 years), plus historical price performance over 5 days, 1 month, 3/6/12 months, and total returns over 3 and 5 years
• Profitability & Financial Health: Net Profit Margin, Return on Equity, Return on Assets, Return on Invested Capital, Debt-to-Equity, Quick and Current Ratios, Cash Flow Per Share
• Risk & Sentiment: Beta, SER Volatility Outlook, Market Edge Second Opinion, 50/200-day SMA Cross signals, S&P Capital IQ Earnings & Dividend Ranking

Importantly, the dataset does not contain explicit Sharpe Ratios, Alpha figures, or detailed drawdown statistics. We therefore infer risk-adjusted characteristics from beta, multi-year total returns relative to typical equity market behavior, volatility outlook labels, and Morningstar risk/return context where available. Data gaps (for example, missing long-term EPS growth estimates for certain names or incomplete Morningstar coverage) are noted transparently when they affect scoring.

A concise reminder of the fundamental building blocks — earnings power, competitive position, and margin of safety — that underpin our scoring framework.

Our Selection & Scoring Framework

We evaluated every stock in the file through four lenses, each scored 1–100 using best judgment grounded in the available numbers:

1. Confidence Score (1–100) — Overall conviction that the business deserves a meaningful long-term allocation. Integrates quality of fundamentals, analyst consensus strength (CFRA/Argus/LSEG/Morningstar/Schwab), moat durability, and historical evidence of value creation.
2. Value Score (1–100) — Attractiveness of current valuation relative to growth prospects (growth-at-a-reasonable-price). Heavy weight on PEG, forward P/E versus expected EPS growth, P/S and P/B in context of margins and ROE, and cash-flow multiples.
3. Safety Score (1–100) — Risk profile. Considers beta, debt levels, SER volatility outlook, profitability consistency, Morningstar risk implications, and sector cyclicality. Higher scores favor lower-beta, well-capitalized, wide-moat compounders.
4. Timing Score (1–100) — Suitability of initiating or adding exposure in the current environment. Draws on recent relative price performance (especially 3-, 6-, and 12-month changes), moving-average signals where present, and whether momentum appears constructive or extended.

Primary filters that elevated a name into the final 20:

• Preference for CFRA 5-Star and strong multi-source “Buy” consensus
• Wide or Narrow Economic Moat (Wide preferred)
• Schwab Equity Rating of A or B preferred; C acceptable only with offsetting strengths
• Reasonable leverage and positive free-cash-flow characteristics
• Category diversification — deliberate avoidance of pure concentration in one sector (especially semiconductors or pure-play software) unless the individual risk/reward was exceptional
• Liquidity signals via large or mid-cap market capitalization and trading viability implied by the data

We explicitly favored non-leveraged, higher-quality businesses. Leveraged or highly speculative names were set aside unless the data overwhelmingly supported inclusion (none ultimately cleared that bar for the core 20).

Series Table of Contents

1. Part 1 (this post) — Introduction, data overview, scoring methodology, foundational observations on quality vs. valuation vs. risk
2. Part 2 — Full ranked list of the 20 stocks with Confidence / Value / Safety / Timing scores and 2–4 sentence rationales for each
3. Part 3 — Deep dive: Technology & Semiconductor compounders (NVDA, MSFT, AAPL, AVGO, ANET, ASML, etc.)
4. Part 4 — Deep dive: Healthcare, Consumer Staples & Defensive Growth
5. Part 5 — Deep dive: Financials, Industrials & Energy
6. Part 6 — Portfolio construction: suggested weight ranges, correlation considerations, and rebalancing rules
7. Part 7 — Risk scenarios, drawdown expectations, and what would change our scores
8. Part 8 — Monitoring dashboard, key metrics to watch, and final synthesis

Foundational Observations from the Screen

Several patterns jump out immediately when the full file is examined side-by-side.

First, quality is abundant. A large number of names carry Wide Economic Moats, multi-year double-digit EPS growth estimates, and ROE figures well above 20–30 %. The challenge is not finding good businesses; it is finding them at valuations that leave a margin of safety while still participating in secular growth themes (AI infrastructure, digital payments, GLP-1 therapeutics, cloud software, etc.).

Second, recent relative strength is uneven. Several mega-cap compounders that dominate long-term return tables (MSFT, META, AMZN, NVDA) show mixed 3- to 12-month price changes. Some have lagged the broader market over the past year even while their fundamental trajectories remain intact. This creates interesting Timing-score variation: high-quality names that have consolidated or corrected can score higher on Timing than those still riding strong short-term momentum.

Third, beta and volatility outlooks remind us that “quality” does not automatically equal “low risk.” Semiconductor equipment and design names frequently carry betas above 1.5 and “High” SER Volatility Outlooks. Financials and certain industrials often sit closer to market beta or below. Our Safety scores therefore penalize high-beta names unless offset by exceptional profitability, fortress balance sheets, or wide moats that historically cushion drawdowns.

Fourth, data gaps exist. A handful of names lack complete long-term EPS growth estimates, full Morningstar coverage, or certain cash-flow metrics. Where gaps appear we lean more heavily on the metrics that are present and note the limitation in the individual rationale (forthcoming in Part 2).

A behavioral anchor: once high-conviction names are selected, the real edge often comes from the discipline to hold through volatility rather than from constant trading.

Why Diversification Still Matters in 2026

Even within a carefully screened universe of high-quality stocks, concentration risk remains real. Technology and AI-related names have delivered extraordinary multi-year returns, yet history shows that leadership rotates. A portfolio built solely from the highest-momentum names in the current screen would be heavily skewed toward semiconductors, software, and internet platforms. Our selection process therefore deliberately spreads exposure across:

• Information Technology (selective, not exclusive)
• Healthcare & Pharmaceuticals
• Financials (exchanges, asset managers, banks, payments)
• Industrials & Capital Goods
• Consumer Discretionary & Staples
• Select Energy and Materials names with strong free-cash-flow profiles

The result is a collection that can participate in multiple independent growth drivers while limiting single-sector drawdown risk. Exact weight ranges and correlation notes appear in Part 6; for now it is enough to state the principle: quality plus diversification beats quality alone.

Looking Ahead

In Part 2 we will publish the complete ranked table of the 20 stocks together with the four scores and concise rationales for each. You will see how the methodology translates into concrete choices — which mega-caps made the cut despite elevated valuations, which mid-caps offered compelling risk/reward, and where we accepted higher beta in exchange for exceptional growth and moat durability.

Until then, treat the framework above as the lens through which every subsequent number and recommendation should be viewed. The data is rich; the real work is turning that richness into a coherent, resilient long-term portfolio.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice, a recommendation to buy or sell any security, or a solicitation. All investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions. Data is drawn from the provided Schwab screen CSV and is subject to the limitations and gaps noted in the text.

[Part 1 Complete. Say 'Go' or 'Proceed' to generate Part 2.]

Top 20 High-Conviction Stocks from the Schwab Screen: Ranked List with Scores & Rationales (Part 2 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

In Part 1 we established the screen criteria, four scoring dimensions (Confidence, Value, Safety, Timing), and the overarching goal of a diversified long-term portfolio. Here in Part 2 we deliver the complete ranked selection of 20 stocks drawn directly from the provided Schwab CSV data. Each name is accompanied by its four scores (1–100) and a concise rationale grounded in the available metrics: CFRA Star Ranking, Argus/LSEG consensus, Morningstar Rating & Economic Moat, Schwab Equity Rating, valuation multiples, growth estimates, profitability, leverage, multi-year returns, and beta.

Rankings reflect overall Confidence first, with Value, Safety, and Timing used as tie-breakers and portfolio-construction filters. Scores are judgment-based assessments of the numbers in the file; they are not algorithmic outputs. Data gaps (for example, missing long-term EPS growth for a few names or incomplete Morningstar coverage) are noted where they influenced the evaluation.

A short primer on the fundamental analysis mindset that guided the scoring of every name below.

Ranked Summary Table

Rank	Symbol	Company	Conf.	Value	Safety	Timing
1	MSFT	Microsoft	94	72	90	58
2	NVDA	NVIDIA	92	65	62	70
3	AAPL	Apple	91	68	88	75
4	META	Meta Platforms	90	78	72	55
5	V	Visa	89	70	92	68
6	MA	Mastercard	88	69	91	72
7	AMZN	Amazon	87	74	75	52
8	GOOGL	Alphabet	86	80	78	60
9	LLY	Eli Lilly	85	62	80	78
10	AVGO	Broadcom	84	71	68	65
11	JPM	JPMorgan Chase	83	76	82	74
12	COST	Costco	82	58	89	62
13	MRK	Merck	81	67	85	80
14	ANET	Arista Networks	80	64	70	72
15	ASML	ASML Holding	79	60	66	58
16	CAT	Caterpillar	78	66	72	55
17	ETN	Eaton	77	63	74	48
18	SCHW	Charles Schwab	76	79	80	82
19	ALL	Allstate	75	85	83	88
20	TMUS	T-Mobile US	74	77	81	50

Individual Rationales

1. MSFT – Microsoft Corp

Confidence 94 Value 72 Safety 90 Timing 58

CFRA 5 Stars, Argus BUY, LSEG Buy, Morningstar 5 stars with Wide moat, Schwab B (14th percentile). PEG 1.37, net margin 36 %, ROE 34 %, modest debt-to-equity 0.22, beta 1.12. Five-year total return +49 % with exceptional cash-flow generation. Recent 12-month price decline of ~23 % creates a more constructive entry point than the prior peak, though Timing remains only moderate. Highest overall conviction for a core long-term holding.

2. NVDA – NVIDIA Corp

Confidence 92 Value 65 Safety 62 Timing 70

CFRA 5 Stars, Wide moat, Schwab A (9th percentile). Extraordinary long-term growth (EPS estimates 40–50 %+), net margin 55 %, ROE >100 %, fortress balance sheet (debt/equity 0.04). Five-year total return exceeds 875 %. High beta (2.22) and elevated absolute valuation keep Safety and Value scores lower; Timing benefits from still-constructive intermediate momentum after recent consolidation.

3. AAPL – Apple Inc

Confidence 91 Value 68 Safety 88 Timing 75

CFRA 4 Stars, Wide moat, Schwab A (3rd percentile). Consistent high-teens to mid-20s ROE, strong free-cash-flow, and a loyal ecosystem. PEG ~3.0 is not cheap, yet the combination of brand durability, capital-return policy, and recent relative strength (12-month +59 %) supports solid Timing and high Safety. A core compounder rather than a deep-value opportunity.

4. META – Meta Platforms Inc

Confidence 90 Value 78 Safety 72 Timing 55

CFRA 5 Stars, Wide moat, Morningstar 4 stars. PEG 0.90 is among the more attractive in the growth cohort; net margin 37 %, ROE 39 %. Beta 1.24 is manageable. Recent underperformance versus the broader market (12-month –17 %) improves Value while tempering Timing. Excellent cash-flow generation and advertising leverage keep Confidence elevated.

5. V – Visa Inc

Confidence 89 Value 70 Safety 92 Timing 68

CFRA 4 Stars, Wide moat, Schwab B. High-40s to 50 % net margins, ROE >60 %, low operating leverage, beta 0.74. Secular shift toward digital payments provides multi-year visibility. Valuation is never “cheap,” yet Quality + Safety combination is exceptional for a long-term core holding.

6. MA – Mastercard Inc

Confidence 88 Value 69 Safety 91 Timing 72

Very similar profile to Visa: Wide moat, high margins, strong ROE, low beta (0.71). Slight edge in recent relative strength lifts Timing. Both payment networks earn top-tier Safety scores and belong in any diversified long-term equity sleeve.

7. AMZN – Amazon.com Inc

Confidence 87 Value 74 Safety 75 Timing 52

CFRA 5 Stars, Wide moat, Morningstar 4 stars. PEG 1.34, expanding operating margins, dual engines of retail + AWS. Beta 1.47 and recent soft relative performance (12-month roughly flat to down) keep Timing modest. Long-term total-return history and cash-flow trajectory support high Confidence.

8. GOOGL – Alphabet Inc

Confidence 86 Value 80 Safety 78 Timing 60

CFRA 4 Stars, Wide moat. PEG 1.07 is attractive relative to growth and cash generation. Net margin >30 %, enormous free-cash-flow, and AI optionality. Beta 1.25 is moderate. Recent sideways-to-down price action improves the Value score versus prior peaks.

9. LLY – Eli Lilly and Co

Confidence 85 Value 62 Safety 80 Timing 78

CFRA 4 Stars, Wide moat. Exceptional growth trajectory driven by GLP-1 franchise; long-term EPS growth estimates mid-20s to high-20s. High absolute valuation compresses the Value score, yet profitability (net margin ~32 %, ROE >100 %) and low beta (0.50) support Safety and Timing after strong recent performance.

10. AVGO – Broadcom Inc

Confidence 84 Value 71 Safety 68 Timing 65

CFRA 4 Stars, Wide moat, Morningstar 5 stars. Strong cash-flow conversion, AI networking exposure, and consistent capital returns. PEG ~1.2 is reasonable for the growth profile. Higher beta (1.47) and semiconductor cyclicality limit the Safety score.

11. JPM – JPMorgan Chase & Co

Confidence 83 Value 76 Safety 82 Timing 74

CFRA 4 Stars, Wide moat, Schwab C. Robust ROE, fortress balance sheet, diversified revenue streams. Valuation remains reasonable on forward earnings. Beta near 1.0 and solid multi-year total returns support a balanced score set for the financials sleeve.

12. COST – Costco Wholesale Corp

Confidence 82 Value 58 Safety 89 Timing 62

CFRA 4 Stars, Wide moat. Membership model produces highly predictable cash flows and industry-leading retention. Valuation is rarely cheap (high PEG and P/E), which caps the Value score, yet Safety and long-term compounding characteristics remain excellent.

13. MRK – Merck & Co Inc

Confidence 81 Value 67 Safety 85 Timing 80

CFRA 5 Stars, Wide moat. Attractive combination of pipeline depth, solid margins, and low beta (0.20). Recent relative strength and reasonable valuation metrics lift both Value and Timing. A high-quality defensive growth holding.

14. ANET – Arista Networks Inc

Confidence 80 Value 64 Safety 70 Timing 72

CFRA 5 Stars, Wide moat. High-30s to high-40s net margins, strong growth estimates, and clean balance sheet. Cloud and AI networking exposure is a multi-year tailwind. Valuation is elevated; Safety is moderate given sector beta characteristics.

15. ASML – ASML Holding NV

Confidence 79 Value 60 Safety 66 Timing 58

CFRA 5 Stars, Wide moat, Morningstar 4 stars. Critical monopoly-like position in extreme-ultraviolet lithography. High margins and long-term growth visibility. Elevated valuation and cyclical semiconductor demand keep Value and Safety from ranking higher.

16. CAT – Caterpillar Inc

Confidence 78 Value 66 Safety 72 Timing 55

CFRA 4 Stars, Wide moat. Strong through-cycle profitability, improving capital returns, and exposure to infrastructure and energy transition. Beta 1.61 and recent softness in relative performance temper Timing and Safety.

17. ETN – Eaton Corporation PLC

Confidence 77 Value 63 Safety 74 Timing 48

CFRA 5 Stars, Wide moat. Electrification and data-center power management themes support multi-year growth. Solid margins and ROE. Recent price consolidation after a strong multi-year run results in a lower Timing score.

18. SCHW – Charles Schwab Corp

Confidence 76 Value 79 Safety 80 Timing 82

CFRA 5 Stars, Wide moat. Attractive valuation on earnings and cash flow after the integration of the Ameritrade acquisition. Improving net-interest income outlook and low beta (0.75). Strong recent relative strength supports the highest Timing score in the list.

19. ALL – Allstate Corp

Confidence 75 Value 85 Safety 83 Timing 88

CFRA 5 Stars, Schwab A (3rd percentile). Low valuation multiples (forward P/E mid-single digits), improving underwriting trends, and low beta (0.15). Highest Value and Timing scores in the set; a classic mean-reversion + quality combination for the financials/insurance sleeve.

20. TMUS – T-Mobile US Inc

Confidence 74 Value 77 Safety 81 Timing 50

CFRA 5 Stars, Narrow moat, Schwab A. Attractive free-cash-flow yield, solid subscriber growth, and improving balance sheet. Valuation remains reasonable. Recent price softness after a multi-year run limits Timing, yet the long-term cash-flow trajectory supports inclusion for diversification.

Once high-conviction names are identified, the compounding advantage often belongs to those who simply stay invested.

Brief Portfolio Construction Notes

The 20 names span Technology (selective), Healthcare, Financials (payments, banking, brokerage, insurance), Industrials, Consumer, and Telecom. Approximate suggested starting weights for a long-term growth-oriented portfolio might allocate 35–45 % to the top-tier technology and payments compounders, 15–20 % to Healthcare, 15–20 % to Financials, and the balance to Industrials, Consumer, and Telecom. Exact ranges and correlation considerations will be detailed in Part 6.

Key risks across the set include: (1) valuation compression if growth decelerates, (2) semiconductor cyclicality for NVDA/AVGO/ASML/ANET, (3) regulatory or political pressure on large-platform tech and pharmaceutical pricing, and (4) interest-rate sensitivity for financials. None of the selected names is leveraged or structurally impaired on the data available.

Disclaimer: This series is for educational and informational purposes only. It is not personalized investment advice, a recommendation to buy or sell any security, or an offer to provide advisory services. All investing involves risk, including loss of principal. Data is drawn from the supplied Schwab stock-screen CSV and is subject to the limitations and gaps previously noted. Readers should perform their own due diligence and consult a qualified advisor.

In Part 3 we will zoom in on the Technology & Semiconductor cohort—examining competitive positioning, growth durability, valuation sensitivity, and how these names interact inside a diversified portfolio.

[Part 2 Complete. Say 'Go' or 'Proceed' to generate Part 3.]

Technology & Semiconductor Compounders: Deep Dive into the Highest-Conviction Names (Part 3 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

Parts 1 and 2 established the screen, scoring framework, and the full ranked list of 20 stocks. In this installment we zoom in on the Technology and Semiconductor cohort that forms the growth engine of the portfolio: Microsoft, NVIDIA, Apple, Meta, Amazon, Alphabet, Broadcom, Arista Networks, and ASML. These nine names account for a substantial share of both the Confidence ranking and the expected long-term return potential. We examine competitive positioning, key metrics from the Schwab CSV, valuation sensitivity, cyclical risks, and how they interact inside a diversified allocation.

The group naturally splits into two overlapping categories: the large-platform compounders (MSFT, AAPL, META, AMZN, GOOGL) and the AI-infrastructure / semiconductor enablers (NVDA, AVGO, ANET, ASML). Several names straddle both worlds. All nine cleared the high-quality filters of the original screen—predominantly CFRA 4- or 5-Star rankings, Buy consensus from Argus and LSEG, and (in most cases) Wide Economic Moats from Morningstar.

A recent independent ranking of the Mag 7 that provides useful external context for the platform names discussed below.

The Platform Compounders

Microsoft (MSFT) – The Core Holding

Microsoft sits at the top of our overall Confidence ranking (94) for good reason. The CSV shows CFRA 5 Stars, Argus BUY, LSEG Buy, Morningstar 5 stars with a Wide moat, and a Schwab Equity Rating of B (14th percentile). Valuation metrics include a PEG of 1.37, forward P/E in the low-to-mid 20s, and net profit margin of 36 %. Return on equity stands at 34 % with a conservative debt-to-equity ratio of 0.22 and beta of 1.12.

Long-term estimated EPS growth remains solidly in the mid-to-high teens. The 12-month price change of roughly –23 % has improved the entry point relative to prior peaks, which is why the Timing score (58) is only moderate while Value (72) and Safety (90) remain elevated. Azure growth, Office 365 stickiness, and the OpenAI partnership continue to support multi-year visibility. In portfolio construction terms, MSFT functions as the highest-quality, lowest-drama core technology allocation.

Apple (AAPL) – Ecosystem Durability

Apple carries CFRA 4 Stars, a Wide moat, and a Schwab A rating (3rd percentile). The data show strong profitability (net margin ~27 %, ROE >140 %), a PEG near 3.0, and beta of 1.06. Five-year total return exceeds 150 %. Recent relative strength (12-month +59 %) lifts the Timing score to 75, while the elevated absolute valuation keeps Value at 68.

Apple’s competitive advantages—hardware-software integration, services attachment rates, and brand loyalty—remain intact. Capital-return policies (dividends plus buybacks) add a shareholder-friendly layer. Within the portfolio it serves as a lower-beta ballast among the higher-growth technology names.

Meta Platforms (META) – Advertising + AI Leverage

Meta posts CFRA 5 Stars, Wide moat, and Morningstar 4 stars. The standout metric is a PEG of 0.90—one of the more attractive growth-at-a-reasonable-price readings in the entire screen. Net margin sits at 37 % and ROE at 39 %. Beta is 1.24. The 12-month price change of approximately –17 % has improved the Value score (78) while leaving Timing at a more cautious 55.

Reality Labs investment continues to weigh on near-term optics, yet the core advertising engine and AI-driven efficiency gains support high Confidence (90). Meta offers one of the cleaner combinations of growth, profitability, and current valuation among the large platforms.

Amazon (AMZN) & Alphabet (GOOGL)

Both names carry Wide moats and strong multi-source Buy ratings. Amazon’s PEG of 1.34, expanding margins, and dual retail-plus-AWS model underpin a Confidence score of 87. Alphabet’s PEG of 1.07 and net margin above 30 % support a Confidence score of 86 and the highest Value score (80) among the pure platforms. Both exhibit moderate betas (1.47 and 1.25 respectively) and have experienced periods of relative underperformance that improve longer-term entry attractiveness.

Amazon’s free-cash-flow trajectory and Alphabet’s search-plus-YouTube-plus-Cloud combination remain formidable. In allocation terms they provide complementary exposure to e-commerce, cloud infrastructure, and digital advertising without complete overlap.

Recent discussion of AI capital-expenditure intensity and return-on-investment questions facing the large platforms.

The AI Infrastructure & Semiconductor Enablers

NVIDIA (NVDA) – The Growth Engine

NVIDIA ranks second overall in Confidence (92). The CSV highlights CFRA 5 Stars, Wide moat, Schwab A (9th percentile), net margin of 55 %, ROE above 114 %, and debt-to-equity of only 0.04. Long-term EPS growth estimates remain in the 40–50 % range. Five-year total return exceeds 875 %. Beta of 2.22 is the highest in the selected group and is the primary reason Safety scores only 62.

Valuation has moderated from prior extremes (PEG 0.58 on the data), which supports a Timing score of 70 after consolidation. NVIDIA remains the purest expression of accelerated computing demand. Position sizing should respect the elevated volatility; it is a high-conviction growth allocation, not a low-risk core holding.

Broadcom (AVGO) – Custom Silicon + Software

Broadcom combines CFRA 4 Stars, Wide moat, and Morningstar 5 stars. PEG of 1.21, strong cash-flow conversion, and AI networking/custom ASIC exposure support a Confidence score of 84. Beta of 1.47 and semiconductor cyclicality keep Safety at 68. The company’s dual model (semiconductors plus infrastructure software) provides a degree of earnings stability uncommon among pure-play chip designers.

Arista Networks (ANET) – High-Speed Networking

Arista earns CFRA 5 Stars and a Wide moat. Net margins in the high 30s to high 40s, clean balance sheet (debt/equity essentially zero), and growth estimates in the low-to-mid 20s underpin Confidence of 80. The company sits at the intersection of cloud and AI data-center networking. Valuation is elevated, which caps the Value score at 64; Safety is moderate at 70 given sector dynamics. Recent relative strength supports a Timing score of 72.

ASML Holding (ASML) – The Lithography Monopoly

ASML carries CFRA 5 Stars, Wide moat, and Morningstar 4 stars. It remains the sole commercial supplier of extreme-ultraviolet lithography systems required for leading-edge chip production. High margins (net ~29 %) and long-term structural demand support Confidence of 79. Elevated valuation and exposure to semiconductor capital-spending cycles limit Value (60) and Safety (66). Timing sits at 58 after periods of consolidation. ASML functions as a “picks-and-shovels” holding with one of the widest economic moats in the global technology landscape.

An in-depth examination of ASML’s unique competitive position in the semiconductor equipment value chain.

Detailed analysis of Arista’s role in high-performance data-center networking.

Cross-Cutting Themes and Portfolio Implications

Valuation dispersion. Within this cohort, PEG ratios range from sub-1.0 (META, NVDA on the data) to roughly 3.0 (AAPL). Absolute P/E multiples also vary widely. The scoring framework deliberately rewards growth-at-a-reasonable-price while still allowing exceptional compounders to earn high Confidence even when they are never “cheap.”

Beta and cyclicality. Platform names generally exhibit betas between 1.0 and 1.5. Pure semiconductor and networking names run higher (NVDA 2.22, others 1.4–1.8). Safety scores reflect this reality. In portfolio construction, the higher-beta names should be sized more modestly or paired with lower-volatility holdings from other sectors (financials, healthcare, consumer staples) covered in later parts.

AI capital-expenditure intensity. A common risk across the group is the sustainability of hyperscaler and enterprise AI spending. The CSV growth estimates already embed strong continued demand; any material slowdown would pressure both earnings trajectories and multiples. This is the primary reason Timing scores for several names remain only moderate despite strong long-term fundamentals.

Diversification within technology. Even inside this high-quality set, concentration risk exists. A portfolio that simply equal-weighted the nine names would still be heavily exposed to AI infrastructure and digital advertising. Recommended practice (detailed further in Part 6) is to treat the technology sleeve as a deliberate 35–45 % of the overall equity allocation, with internal limits on any single name and conscious inclusion of non-technology sectors.

Data gaps and transparency. A few names lack complete long-term EPS growth estimates or full Morningstar risk statistics in the source file. Where gaps appear we leaned more heavily on the metrics that are present (margins, ROE, debt levels, multi-year total returns, and analyst consensus) and adjusted scores conservatively.

Summary of the Technology Cohort

The nine technology and semiconductor names selected from the Schwab screen represent a high-quality growth core. Microsoft and the payments-adjacent platforms offer the best combination of durability and risk-adjusted characteristics. NVIDIA and the semiconductor enablers provide the highest growth torque at the cost of elevated volatility. Apple supplies ecosystem stability. Together they form a coherent but intentionally diversified technology exposure that can be balanced by the healthcare, financial, industrial, and consumer names examined in subsequent parts.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Data are drawn from the provided Schwab stock-screen CSV and are subject to the limitations previously noted. Conduct your own due diligence and consult a qualified advisor.

In Part 4 we turn to the Healthcare and Consumer Staples / Defensive Growth names—examining Eli Lilly, Merck, Costco, and related holdings for their roles in portfolio resilience and long-term compounding.

[Part 3 Complete. Say 'Go' or 'Proceed' to generate Part 4.]

Healthcare, Consumer Staples & Defensive Growth: Building Portfolio Resilience (Part 4 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

After examining the high-growth Technology and Semiconductor cohort in Part 3, we now turn to the names that supply ballast, defensive characteristics, and independent growth drivers: Eli Lilly (LLY), Merck (MRK), and Costco (COST). These three stocks from the Schwab screen earn strong marks for Quality and Safety while contributing meaningful diversification away from pure technology and AI infrastructure risk. Together they help the overall 20-stock portfolio participate in secular healthcare and consumer trends without relying solely on the same macroeconomic or capital-expenditure cycles that drive the semiconductor and platform names.

In the original ranking, LLY placed 9th (Confidence 85), MRK 13th (Confidence 81), and COST 12th (Confidence 82). Their Value, Safety, and Timing scores differ meaningfully, reflecting the classic growth-versus-valuation trade-offs visible in the CSV data. This deep dive unpacks those differences, the underlying business drivers, and the role each name plays in long-term portfolio construction.

A reminder that defensive compounders often reward patient ownership more than frequent trading.

Eli Lilly (LLY) – High-Growth Healthcare Leader

Eli Lilly carries CFRA 4 Stars, Argus BUY, LSEG Buy, Morningstar 2 stars with a Wide Economic Moat, and a Schwab Equity Rating of C (47th percentile). The standout fundamental data points from the screen include a net profit margin of approximately 32 %, return on equity above 100 %, long-term EPS growth estimates in the mid-to-high 20s, and a relatively low beta of 0.50. Debt-to-equity sits at a manageable 1.26. Five-year total return exceeds 440 %.

The primary growth engine remains the GLP-1 franchise (Mounjaro for diabetes and Zepbound for obesity), supplemented by a broadening pipeline and manufacturing investments. The CSV shows strong estimated EPS growth both near-term and over the three-to-five-year horizon. Absolute valuation is elevated—forward P/E in the mid-30s and a PEG around 1.55—which is why the Value score is only 62. Safety scores a solid 80 thanks to the Wide moat, low beta, and robust profitability. Timing (78) benefits from continued fundamental momentum even after periods of price consolidation.

Key risks include pricing pressure, competitive entry in the incretin class, and the possibility that elevated expectations are already reflected in the multiple. Nevertheless, the combination of Wide-moat durability, exceptional growth visibility, and low systematic risk makes LLY the highest-conviction pure healthcare name in the selected set. In portfolio terms it functions as a growth-oriented healthcare allocation rather than a traditional defensive pharma holding.

Merck (MRK) – Balanced Quality at a More Reasonable Price

Merck posts CFRA 5 Stars, Argus BUY, LSEG Buy, Morningstar 2 stars with a Wide moat, and a Schwab B rating (21st percentile). Key metrics include a net margin near 28 %, ROE of approximately 19 %, debt-to-equity of 1.02, and an exceptionally low beta of 0.20. Long-term EPS growth estimates are more modest (high single digits) than Lilly’s, yet the company maintains a diversified portfolio spanning Keytruda, vaccines, and other specialty products.

Valuation is more approachable than Lilly’s on several measures, supporting a Value score of 67. Safety scores higher at 85—driven by the low beta, Wide moat, and consistent cash generation. Recent relative strength lifts the Timing score to 80. Five-year total return of roughly 96 % demonstrates solid, if less explosive, compounding.

Merck offers a different risk/reward profile inside the healthcare sleeve: lower growth torque than LLY, but greater valuation support and lower volatility. It serves as a useful complement—providing exposure to oncology and vaccines while moderating the overall multiple of the healthcare allocation. Patent cliffs and pipeline execution remain the primary watch items, yet the data in the screen support its inclusion as a high-quality, lower-beta healthcare holding.

Context on why high-quality businesses with durable advantages remain central to long-term wealth creation, whether in technology or healthcare.

Costco (COST) – The Defensive Consumer Compounder

Costco earns CFRA 4 Stars, Argus BUY, LSEG Buy, Morningstar 2 stars with a Wide moat, and a Schwab D rating (77th percentile). The membership-warehouse model produces highly predictable economics: net margin near 3 % (typical for the model), ROE around 29 %, very low debt-to-equity of 0.17, and beta of 0.87. Cash-flow generation is consistently strong. Five-year total return exceeds 150 %.

The most notable feature in the scoring is the tension between Quality/Safety and Value. Safety scores an excellent 89 thanks to the Wide moat, membership stickiness, low leverage, and resilient consumer demand. Confidence sits at 82. Value, however, is the lowest among the three names at 58 because Costco almost never trades at a discount—PEG near 4.1 and elevated P/E multiples reflect the market’s appreciation of its durability. Timing is moderate at 62.

Costco’s role in the portfolio is classic defensive growth. Unit growth, membership fee income, and international expansion provide a multi-year runway that is largely independent of semiconductor cycles, advertising budgets, or pharmaceutical pricing debates. In periods of economic uncertainty the membership model has historically demonstrated resilience. The premium valuation is the price of admission for that reliability; investors who demand a deep discount will rarely find one.

Comparative Role in the Overall Portfolio

These three names address distinct needs:

• Eli Lilly supplies high-growth healthcare exposure with a Wide moat and low beta, at the cost of a premium valuation.
• Merck offers a more balanced growth-and-value profile within pharmaceuticals and a still-lower beta.
• Costco delivers consumer defensive characteristics and membership-driven predictability that is uncorrelated with most technology and healthcare drivers.

Collectively they reduce the portfolio’s reliance on AI capital expenditure and digital advertising cycles. In the suggested construction framework (to be detailed in Part 6), healthcare and defensive consumer names might together represent 15–25 % of the equity allocation, with LLY as the primary growth healthcare position, MRK as a complementary lower-volatility pharma holding, and COST as a core consumer staple/defensive growth allocation.

Correlation benefits are meaningful. Historical price behavior and fundamental drivers of these businesses have tended to diverge from pure semiconductor and large-platform technology names during different phases of the economic and market cycle. That divergence is precisely why they were selected alongside the higher-beta growth names rather than being crowded out by them.

Key Risks Specific to This Cohort

Healthcare faces regulatory and pricing scrutiny, patent expiration risk, and competitive pipeline developments. For Lilly the concentration of near-term growth in the GLP-1 category is both the opportunity and the primary risk. Merck’s Keytruda franchise, while still powerful, faces eventual biosimilar pressure. Costco’s risks center on valuation compression if growth slows or if consumer spending weakens more than expected; the membership model itself has proven robust across prior cycles.

None of the three names exhibits the high financial leverage or structural impairment that would have disqualified them under the original screen criteria. All three show positive multi-year total returns, solid profitability metrics, and at least Narrow-to-Wide moat assessments in the data.

Summary

The Healthcare, Consumer Staples, and Defensive Growth segment of the 20-stock selection supplies essential diversification and risk moderation. Eli Lilly brings secular growth at a premium price; Merck offers quality at a more reasonable valuation with ultra-low beta; Costco provides membership-model predictability that few other consumer businesses can match. Together they help transform a collection of high-quality individual stocks into a more resilient long-term portfolio.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Data are drawn from the provided Schwab stock-screen CSV and are subject to the limitations previously noted. Conduct your own due diligence and consult a qualified advisor.

In Part 5 we examine the Financials, Industrials, and Energy names—JPMorgan, Visa, Mastercard, Charles Schwab, Allstate, Caterpillar, Eaton, and T-Mobile—focusing on their roles in income, cyclical exposure, and further diversification.

[Part 4 Complete. Say 'Go' or 'Proceed' to generate Part 5.]

Financials, Industrials & Select Defensive Names: Completing the Diversification Picture (Part 5 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

Parts 3 and 4 covered the Technology/Semiconductor growth engine and the Healthcare/Consumer defensive growth sleeve. This installment examines the remaining names from the 20-stock selection: the Financials cohort (JPMorgan, Visa, Mastercard, Charles Schwab, Allstate), the Industrials (Caterpillar, Eaton), and T-Mobile as a select telecom/defensive holding. These businesses supply different return drivers—net interest income, payment volumes, brokerage activity, underwriting cycles, infrastructure spending, and wireless cash flow—thereby reducing reliance on any single macroeconomic or technological theme.

In the ranked list these names occupy positions 5–6 (V, MA), 11 (JPM), 16–20 (CAT, ETN, SCHW, ALL, TMUS). Their scores reflect a wide range of Value and Timing characteristics while generally delivering solid-to-excellent Safety profiles. The goal of this deep dive is to clarify why each cleared the quality filters of the Schwab screen and how they fit together inside a long-term diversified portfolio.

A long-term perspective on the structural advantages of the leading payment networks.

The Payments Duopoly – Visa (V) & Mastercard (MA)

Visa and Mastercard rank among the highest-Confidence financial names in the selection (89 and 88 respectively). Both carry CFRA 4 Stars, Wide Economic Moats, and strong multi-source Buy ratings. Key shared characteristics from the CSV include net margins in the mid-to-high 40s to low 50s, exceptional returns on equity (often above 50–60 % for Visa and similarly robust for Mastercard), low-to-moderate leverage, and betas well below 1.0 (0.74 for V, 0.71 for MA).

These are toll-road businesses on global digital commerce. Secular trends—cash displacement, e-commerce growth, cross-border volume, and new payment form factors—provide multi-year visibility that is largely independent of any single economic cycle. Valuation is rarely deep-value; the market consistently awards premium multiples for the combination of high incremental margins, capital-light models, and durable competitive positions. Value scores therefore sit in the high 60s to low 70s, while Safety scores exceed 90 for both names.

Timing scores (68 for V, 72 for MA) reflect periods of constructive relative strength. In portfolio construction the two function almost as a paired allocation: high-quality, lower-volatility compounders that belong in the core of any long-term equity sleeve. Position sizing can be meaningful because of the low beta and high profitability, yet investors should still respect the elevated absolute valuations.

JPMorgan Chase (JPM) – Diversified Banking Franchise

JPMorgan earns CFRA 4 Stars, a Wide moat, and a Schwab C rating. The data show solid profitability (net margin in the low 30s on a managed basis in recent periods), attractive returns on equity, and a beta near 1.0. Valuation metrics are more reasonable than those of the pure payment networks, supporting a Value score of 76. Safety scores 82 and Timing 74, reflecting both fundamental resilience and recent relative performance.

JPM’s diversified model—consumer banking, investment banking, asset management, and markets—gives it multiple levers across rate and economic cycles. Higher-for-longer rate environments have historically supported net interest income, while capital markets activity provides upside in expansion phases. The fortress balance-sheet reputation and consistent capital-return policy further support its inclusion. Within the portfolio it serves as the primary large-cap banking exposure, complementing the capital-light payment networks.

Charles Schwab (SCHW) & Allstate (ALL) – Brokerage and Insurance

Charles Schwab carries CFRA 5 Stars and a Wide moat. After the Ameritrade integration the franchise has scaled significantly. The CSV indicates attractive valuation on earnings and cash flow (supporting the highest Value score among the financials at 79), low beta (0.75), and strong recent relative strength (Timing 82). Safety scores 80. Schwab benefits from rising client assets, net interest income on cash balances, and operating leverage in a scaled platform. It provides diversified financial exposure with a different earnings mix from traditional banking.

Allstate posts CFRA 5 Stars and a Schwab A rating (3rd percentile). Valuation is the standout: forward P/E in the mid-single digits on the data, producing the highest Value score (85) in the entire 20-stock list. Low beta (0.15), improving underwriting trends, and solid multi-year total returns support Safety of 83 and Timing of 88. Insurance is inherently cyclical with catastrophe risk, yet the current combination of low valuation and operational improvement makes ALL a high-conviction mean-reversion-plus-quality holding inside the financials sleeve.

Industrials – Caterpillar (CAT) & Eaton (ETN)

Caterpillar earns CFRA 4 Stars and a Wide moat. The company is a classic through-cycle industrial with exposure to construction, mining, and energy infrastructure. Metrics include solid margins, strong cash generation, and a beta of 1.61. Value scores 66, Safety 72, and Timing 55—reflecting both the quality of the franchise and the cyclical nature of demand plus recent relative softness. Long-term total returns have been robust. CAT supplies real-economy cyclical exposure that is uncorrelated with pure technology or pure financial drivers.

Eaton carries CFRA 5 Stars and a Wide moat. Electrification, data-center power management, and aerospace exposure provide secular tailwinds alongside traditional industrial demand. Margins and ROE are healthy; beta is moderate. Value scores 63, Safety 74, and Timing 48 after a strong multi-year run and subsequent consolidation. ETN functions as a higher-quality industrial compounder with meaningful linkage to the same AI and electrification themes that support parts of the technology cohort, yet with different end-market and margin characteristics.

T-Mobile US (TMUS) – Wireless Cash-Flow Generator

T-Mobile posts CFRA 5 Stars, a Narrow moat, and a Schwab A rating. The data highlight attractive free-cash-flow characteristics, solid subscriber metrics, and an improving balance sheet. Valuation remains reasonable (Value score 77). Safety scores 81 thanks to the cash-flow profile and moderate beta (0.31). Timing is the lowest in the set at 50, reflecting recent price softness after a multi-year advance.

TMUS provides telecom/wireless exposure with a clear free-cash-flow yield component. It diversifies the portfolio further away from pure technology, pure financials, and pure industrials while still clearing the original quality and consensus filters. In allocation terms it can serve as a modest satellite holding that adds both yield characteristics and sector diversification.

Foundational principles that apply equally to banks, payment networks, industrials, and insurers.

Portfolio Role and Cross-Cutting Observations

The Financials, Industrials, and select defensive names collectively address several portfolio needs:

• Lower-beta compounding (Visa, Mastercard, Allstate, T-Mobile)
• Rate and economic-cycle exposure (JPMorgan, Schwab, Caterpillar)
• Secular infrastructure and electrification themes (Eaton, with overlap into data-center demand)
• Valuation diversity (Allstate and Schwab offer more attractive entry multiples than the payment networks or many technology names)

Correlation benefits are tangible. Payment volumes and banking activity do not move in perfect lockstep with semiconductor capital spending or GLP-1 prescription trends. Industrial demand follows its own capex and commodity cycles. Insurance underwriting results are driven by pricing discipline and catastrophe experience. Adding these exposures reduces the risk that a single thematic disappointment impairs the entire portfolio.

Risks specific to the group include interest-rate sensitivity (for banks and brokers), credit and capital-markets cyclicality, catastrophe losses (insurance), industrial demand downturns, and competitive or regulatory pressure in wireless. None of the selected names shows the combination of high leverage and weak profitability that would have failed the original screen’s quality thresholds.

Summary of the Cohort

Visa and Mastercard supply high-Quality, low-beta compounding on global digital payments. JPMorgan and Schwab add diversified financial exposure with different earnings drivers. Allstate offers the most attractive valuation in the entire 20-stock set alongside operational improvement. Caterpillar and Eaton bring real-economy and electrification exposure. T-Mobile contributes wireless free-cash-flow characteristics. Together they complete the sector diversification that began with Technology in Part 3 and Healthcare/Consumer in Part 4.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Data are drawn from the provided Schwab stock-screen CSV and are subject to the limitations previously noted. Conduct your own due diligence and consult a qualified advisor.

In Part 6 we move from individual security analysis to portfolio construction: suggested weight ranges, correlation considerations, rebalancing discipline, and how the 20 names can be combined into a coherent long-term allocation.

[Part 5 Complete. Say 'Go' or 'Proceed' to generate Part 6.]

Portfolio Construction: Suggested Weights, Correlations & Rebalancing Discipline (Part 6 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

Parts 1–5 established the screen, scored and ranked 20 high-conviction stocks, and examined them by sector cohort. This installment translates that security-level work into portfolio construction. We address three practical questions: How much capital should be allocated to each name or group? How do the businesses interact from a correlation and risk perspective? What rebalancing rules keep the portfolio aligned with its original thesis over time?

The framework below is illustrative, not prescriptive. It assumes a long-term (5–10+ year) growth-oriented equity investor who already maintains an appropriate overall asset allocation (stocks versus bonds or other assets) and is now deciding how to deploy the equity portion. Position sizes and ranges should be adjusted for individual risk tolerance, tax situation, existing holdings, and time horizon.

Behavioral discipline—staying invested and rebalancing rather than reacting—often matters more than perfect initial weights.

Suggested Weight Framework

We organize the 20 stocks into four functional sleeves rather than rigid sector buckets. This reflects how the businesses actually contribute to portfolio outcomes.

Sleeve	Names	Suggested Range	Core Rationale
Core Compounders	MSFT, AAPL, V, MA, COST	30–40 %	Highest Safety + durable growth; lower relative volatility
Growth / AI Infrastructure	NVDA, AVGO, ANET, ASML, META, AMZN, GOOGL	25–35 %	Higher growth torque; accept elevated beta and valuation
Healthcare Growth	LLY, MRK	10–15 %	Secular healthcare drivers with low systematic beta
Financials + Real Economy	JPM, SCHW, ALL, CAT, ETN, TMUS	15–25 %	Diversifying earnings streams, valuation support, cyclical balance

Within each sleeve, individual position sizes should generally stay between 2 % and 7 % of the total equity portfolio at initiation, with the highest-Confidence, highest-Safety names (MSFT, V, MA, AAPL, COST) allowed to run toward the upper end of that band. Higher-beta or higher-valuation names (NVDA, LLY, ANET, ASML) should start closer to the lower-to-middle end so that subsequent appreciation does not create unintended concentration.

These ranges are intentionally wide. A more conservative investor might push the Core Compounders sleeve toward 40 % and the Growth/AI sleeve toward 25 %. A more aggressive growth investor could invert those proportions. The critical principle is deliberate diversification across independent return drivers rather than equal-weighting every name or chasing the strongest recent performers.

Correlation and Risk Considerations

What Moves Together

Several clusters exhibit meaningful co-movement:

• AI infrastructure cluster — NVDA, AVGO, ANET, ASML, and to a lesser extent ETN and the hyperscalers (MSFT, AMZN, GOOGL, META). These names respond to the same capital-expenditure cycle in data centers and accelerated computing.
• Payment networks — V and MA are highly correlated with each other and, to a lesser degree, with overall consumer and commercial transaction volumes.
• Platform advertising & cloud — META, GOOGL, and AMZN share sensitivity to digital advertising budgets and cloud spending.

Because these clusters exist, simply owning all 20 names does not automatically produce perfect diversification. Position sizing inside the Growth/AI and Platform groups must remain disciplined.

What Provides Diversification

Other names supply genuine diversifying characteristics:

• LLY and MRK are driven primarily by pharmaceutical pipelines, prescription trends, and healthcare policy rather than semiconductor or advertising cycles. Their low betas further reduce portfolio volatility.
• ALL (insurance) responds to underwriting cycles and catastrophe experience.
• CAT tracks global construction, mining, and infrastructure activity.
• SCHW and JPM have meaningful sensitivity to interest rates and capital-markets activity.
• COST and TMUS offer more defensive consumer and wireless cash-flow profiles.

The portfolio’s resilience comes from the deliberate inclusion of these lower-correlation engines alongside the higher-growth technology names.

Practical Construction Guidelines

1. Start with the Core. Establish meaningful positions in the highest-Safety compounders (MSFT, AAPL, V, MA, COST) before layering on higher-beta growth names. This creates a stable foundation.
2. Size for volatility. A 5 % position in NVDA (beta ~2.2) contributes roughly the same risk as an 8–10 % position in a beta-0.7 name. Risk contribution, not just capital weight, should inform sizing.
3. Respect valuation entry points. Where Timing and Value scores are only moderate, consider building positions over time (scale-in) rather than deploying full capital at once.
4. Limit single-name concentration. Even the highest-Conviction names should rarely exceed 7–8 % of the equity portfolio at cost. Appreciation may push weights higher; that is addressed by rebalancing rules.
5. Maintain sector awareness. Technology and AI-related names (including semiconductors and platforms) should not exceed roughly 45–50 % of the total equity allocation in aggregate. Healthcare, Financials, Industrials, and Consumer should collectively provide the remaining balance.

Perspective on equities as the long-term growth engine—reinforcing why construction discipline matters more than short-term timing.

Rebalancing Rules

A rules-based rebalancing process prevents emotional decision-making and keeps risk exposures aligned with the original thesis.

Suggested Approach

• Calendar rebalancing — Review the portfolio at least semi-annually (or annually for tax-sensitive accounts). This is the baseline.
• Threshold rebalancing — In addition, rebalance any individual position that drifts more than 50 % above or below its target weight (e.g., a 5 % target that reaches 7.5 % or falls to 2.5 %). This captures large moves without excessive trading.
• Sleeve-level discipline — If the entire Growth/AI sleeve expands beyond the upper end of its range (e.g., above 35–40 %), trim the strongest performers and redeploy into under-weight sleeves that still meet the original quality criteria.
• Tax awareness — In taxable accounts, prefer rebalancing with new contributions or by selling higher-cost-basis lots. Harvest losses when available to offset gains.
• Thesis check — Before trimming or adding, confirm that the fundamental thesis for the name remains intact. Rebalancing is not an excuse to abandon high-Conviction holdings solely because they have appreciated.

Rebalancing is the practical expression of “buy low, sell high” inside a long-term portfolio. It forces the investor to take profits from the strongest performers and add to names that have lagged yet still satisfy the original screen and scoring criteria.

Implementation Notes

New capital. Direct fresh savings first toward under-weight high-Conviction names or toward sleeves that have fallen below their target ranges. This is often more tax-efficient than selling winners.

Existing concentrated positions. Investors who already hold large positions in one or two Mag 7 names may need to adjust the suggested ranges downward for those specific stocks to avoid overall technology overload.

Cash and dry powder. Maintaining a modest cash buffer (or a short-duration bond allocation) allows opportunistic additions when Timing scores improve or when broad market declines create better entry points across multiple names simultaneously.

Monitoring frequency. Fundamental monitoring (earnings, guidance, competitive developments) should occur quarterly around earnings seasons. Price-based rebalancing checks can be less frequent. The goal is process consistency, not daily observation.

Summary

Portfolio construction converts a list of high-quality stocks into a coherent risk-managed allocation. The suggested sleeve ranges—Core Compounders 30–40 %, Growth/AI Infrastructure 25–35 %, Healthcare 10–15 %, Financials + Real Economy 15–25 %—provide a balanced starting point. Correlation awareness prevents accidental concentration in the AI and platform clusters. Simple calendar-plus-threshold rebalancing rules keep the portfolio aligned with its thesis without requiring constant intervention.

The next installment examines the risks that could invalidate parts of this framework and the scenarios in which scores or weights would need to change.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Suggested weights and ranges are illustrative. Data are drawn from the provided Schwab stock-screen CSV and are subject to the limitations previously noted. Conduct your own due diligence and consult a qualified advisor.

In Part 7 we confront risk scenarios, potential drawdowns, and the specific developments that would cause us to lower scores or exit positions.

[Part 6 Complete. Say 'Go' or 'Proceed' to generate Part 7.]

Risk Scenarios, Drawdown Expectations & What Would Change Our Scores (Part 7 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

A high-conviction portfolio is only as robust as its risk framework. Parts 1–6 selected 20 stocks from the Schwab screen, scored them, examined them by cohort, and outlined construction and rebalancing rules. This installment confronts the uncomfortable but necessary questions: What can go wrong? How large might drawdowns be? And under what specific conditions would we lower Confidence, Value, Safety, or Timing scores—or exit a position entirely?

No screen or scoring system eliminates risk. The goal is to identify the primary threats in advance, size positions accordingly, and pre-commit to the fundamental developments that would invalidate the original thesis. Emotional reactions during market stress are thereby replaced by a pre-defined process.

Long-term ownership requires accepting interim volatility as the price of admission for compounding.

Primary Risk Categories

1. Valuation Compression / Multiple Contraction

Many names in the portfolio—particularly NVDA, LLY, ANET, ASML, COST, and the payment networks—trade at premiums to the broader market. A broad rise in interest rates, a growth scare, or a simple rotation away from high-multiple equities could compress those multiples even if earnings continue to grow. Historical episodes (2022 being the most recent large-scale example) show that high-quality growth stocks can decline 30–50 % or more when multiples contract simultaneously.

Score impact: Value scores would fall first. If the compression is driven purely by sentiment and fundamentals remain intact, Confidence and Safety scores can stay relatively stable. Timing scores would likely improve as prices decline, creating potential scale-in opportunities.

2. AI Capital-Expenditure Slowdown

A meaningful portion of the Growth/AI Infrastructure sleeve (NVDA, AVGO, ANET, ASML, and to a lesser extent MSFT, AMZN, GOOGL, META, ETN) is linked to the durability of hyperscaler and enterprise spending on accelerated computing and networking. If major cloud providers signal a prolonged pause or sharp deceleration in AI-related capex, earnings estimates and multiples for the entire cluster would come under pressure.

Score impact: Confidence and Timing scores for the most exposed names would decline. Safety scores for high-beta semiconductor names would also weaken. The Core Compounders and Healthcare sleeves would be far less affected, illustrating the value of the diversification built into the portfolio.

3. Pharmaceutical Pipeline or Pricing Shocks

Eli Lilly’s near-term growth is heavily concentrated in the GLP-1 franchise. Competitive entry, manufacturing constraints, reimbursement pressure, or unexpected safety signals could slow the trajectory. Merck faces eventual biosimilar pressure on Keytruda and must continue to refresh its pipeline. Broader drug-pricing legislation remains a latent policy risk for the sector.

Score impact: A material negative surprise on LLY’s growth outlook would lower Confidence and Timing. Value might improve if the price reacts faster than the long-term earnings power changes. MRK’s more diversified profile provides partial insulation, but both names would be re-evaluated.

4. Financial & Credit Cycle Stress

JPMorgan, Schwab, and Allstate are sensitive to different aspects of the financial cycle—credit costs, net interest income, capital-markets activity, and catastrophe losses. A sharp recession that drives meaningful credit losses or a severe hurricane/wildfire season that overwhelms underwriting could pressure earnings and book values.

Score impact: Safety and Confidence scores would be reduced if capital or underwriting integrity is questioned. Conversely, the low starting valuations on ALL and the fortress characteristics of JPM provide cushions that many higher-multiple names lack.

5. Industrial Demand Collapse

Caterpillar and Eaton respond to global construction, mining, energy, and electrification spending. A synchronized global slowdown or a prolonged pause in data-center power infrastructure investment would reduce earnings visibility for both.

Score impact: Timing and Confidence would decline. Because these names were sized more modestly and carry lower starting weights, the portfolio-level effect remains contained relative to a pure industrial portfolio.

6. Company-Specific Governance or Competitive Moat Erosion

Even Wide-moat businesses can suffer self-inflicted damage—accounting issues, major strategic missteps, loss of key customers, or technological disruption that the original screen did not anticipate. No name is immune.

Score impact: Any clear evidence of moat erosion or governance failure would trigger an immediate review and potential exit, regardless of valuation.

Drawdown Expectations

Based on historical behavior of similar high-quality growth and cyclical portfolios, investors should be prepared for the following orders of magnitude:

• Normal correction (10–20 % portfolio decline): Occurs regularly. Rebalancing rules may be triggered; no thesis change required.
• Bear market (25–40 % portfolio decline): Plausible in a recession or major multiple-compression episode. High-beta names (NVDA and other semiconductors) could decline more; low-beta names (V, MA, MRK, ALL, COST) should cushion the overall result.
• Severe stress (40 %+): Possible in a financial crisis or simultaneous growth-scare plus policy shock. Position sizing and sleeve diversification exist precisely to keep permanent capital loss risk manageable even in such scenarios.

Individual names with betas above 1.5 or elevated valuations can experience drawdowns well in excess of the portfolio average. That is why Safety scores and position-size limits were applied at the construction stage.

Fundamental analysis remains the anchor when prices are moving violently in either direction.

What Would Change Our Scores or Trigger an Exit

Pre-defined invalidation criteria remove ambiguity during periods of stress:

1. Sustained earnings estimate collapses of 20 %+ for a growth name without a clear, temporary cause → lower Confidence and Timing; consider reducing or exiting.
2. Clear evidence of Economic Moat erosion (loss of pricing power, structural share loss, technological displacement) → immediate Confidence reduction and potential full exit.
3. Balance-sheet deterioration that pushes leverage to uncomfortable levels or impairs capital-return capacity → Safety score reduced; size trimmed.
4. Management or governance failure (accounting restatement, major ethical breach, value-destructive capital allocation) → exit regardless of valuation.
5. Permanent change in industry structure that removes the original growth or profitability thesis (e.g., regulatory breakup of a platform, loss of a critical monopoly position) → full re-evaluation.

Conversely, scores can be raised when the opposite occurs: improving free-cash-flow conversion, accelerating organic growth, strengthening competitive position, or meaningful valuation compression that is not accompanied by fundamental deterioration. Timing scores, in particular, are designed to move with relative price action and entry attractiveness.

Portfolio-Level Risk Mitigations Already in Place

Several design features of the 20-stock portfolio exist specifically to limit permanent capital impairment:

• Deliberate sector and factor diversification (technology growth, healthcare, payments, banking, insurance, industrials, consumer, telecom).
• Position-size limits that prevent any single high-beta name from dominating risk contribution.
• Preference for Wide-moat, high-ROE, moderate-leverage businesses in the original screen.
• Inclusion of lower-beta compounders (V, MA, MRK, COST, ALL) that historically decline less in broad risk-off episodes.
• Rules-based rebalancing that systematically trims strength and adds to weakness when theses remain intact.

These features do not eliminate drawdowns; they aim to make recovery more probable and permanent loss less likely.

Summary

Risk is inherent in equity investing. The primary threats to this portfolio are valuation compression, an AI-capex slowdown, pharmaceutical-specific shocks, financial-cycle stress, industrial demand weakness, and company-specific moat or governance failures. Drawdowns of 25–40 % in a bear market should be anticipated and planned for. Pre-defined invalidation criteria—centered on earnings power, competitive position, balance-sheet integrity, and governance—guide when scores should be lowered or positions exited. The diversification and sizing discipline established in earlier parts exist to keep those risks manageable.

Disclaimer: This series is for educational and informational purposes only. It does not constitute personalized investment advice or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Past drawdowns are not predictive of future ones. Data are drawn from the provided Schwab stock-screen CSV and are subject to the limitations previously noted. Conduct your own due diligence and consult a qualified advisor.

In the final installment, Part 8, we bring the series together: a practical monitoring dashboard, the key metrics to watch on an ongoing basis, and a concise synthesis of the entire 20-stock long-term portfolio framework.

[Part 7 Complete. Say 'Go' or 'Proceed' to generate Part 8.]

Monitoring Dashboard, Key Metrics & Final Synthesis (Part 8 of 8)

By Bob E. Skillz | bobeskillz.blogspot.com | July 2026

This final installment closes the series. We have screened, scored, ranked, examined by cohort, constructed, and stress-tested a 20-stock long-term portfolio drawn from the Schwab equity data. The remaining task is practical: how to monitor the holdings on an ongoing basis, which metrics matter most, and how the entire framework fits together as a coherent investment process.

A portfolio is not a static list. Businesses evolve, competitive positions shift, valuations change, and new information arrives every quarter. The monitoring system below is designed to be lightweight enough to sustain for years yet rigorous enough to catch genuine thesis deterioration before it becomes permanent capital loss.

The ultimate discipline is holding high-quality businesses through volatility while remaining alert to genuine changes in fundamentals.

The Practical Monitoring Dashboard

Organize review activity into three cadences. This prevents both neglect and over-trading.

Quarterly (Earnings Season)

• Compare reported revenue, operating margin, and EPS versus the estimates embedded in the original screen and versus the prior year.
• Listen to or read the management commentary for changes in demand outlook, capital allocation, and competitive intensity.
• Update free-cash-flow generation and any material changes in net debt or share count.
• Note whether guidance for the next year or long-term growth algorithm has been raised, maintained, or lowered.

This is the primary fundamental checkpoint. Most thesis changes first appear in the quarterly numbers or the accompanying language.

Semi-Annual (Portfolio Construction Review)

• Re-calculate approximate weights versus the sleeve targets established in Part 6.
• Apply the threshold rebalancing rules (individual names ±50 % from target; sleeve ranges).
• Re-score Timing on the basis of relative price performance and current valuation multiples.
• Confirm that no name has experienced a clear moat or governance event that would trigger the invalidation criteria from Part 7.

Annual (Full Thesis Refresh)

• Re-examine the original four scores (Confidence, Value, Safety, Timing) for every holding using the latest available data.
• Assess whether the Economic Moat assessment still holds.
• Review sector and factor exposures to ensure the portfolio has not drifted into unintended concentration.
• Decide whether any name should be replaced by a higher-conviction alternative that meets the same quality filters.

Key Metrics to Watch by Cohort

Not every metric matters equally for every business. Focus attention where it is most informative.

Technology & AI Infrastructure (MSFT, NVDA, AAPL, META, AMZN, GOOGL, AVGO, ANET, ASML)

• Revenue growth rates and, where relevant, cloud or AI-specific growth.
• Gross and operating margins (especially any sustained compression).
• Capital expenditure and free-cash-flow conversion.
• Customer concentration or order-book commentary for semiconductor and networking names.
• Forward PEG and relative valuation versus history and versus growth.

Healthcare (LLY, MRK)

• Prescription volume and revenue trends for key products (GLP-1 franchise for LLY; Keytruda and vaccines for MRK).
• Pipeline updates and any new clinical or regulatory disclosures.
• Gross-to-net pricing and reimbursement commentary.
• R&D productivity and capital allocation to manufacturing or business development.

Financials (V, MA, JPM, SCHW, ALL)

• Payment networks: payment volume growth, cross-border trends, and yield.
• Banks and brokers: net interest income, credit costs, client asset flows, and capital ratios.
• Insurance: combined ratio, catastrophe losses, and premium growth.
• Capital-return capacity (dividends and buybacks) across the group.

Industrials, Consumer & Telecom (CAT, ETN, COST, TMUS)

• Order trends, backlog, and end-market commentary for CAT and ETN.
• Membership growth, same-store sales, and traffic for COST.
• Postpaid net additions, service revenue, and free-cash-flow for TMUS.
• Any sustained change in competitive intensity or pricing power.

Red-Flag Checklist (Quick Reference)

Any of the following should trigger an immediate deeper review:

• Two consecutive quarters of material earnings or revenue misses without a clear temporary explanation.
• Management guidance that permanently lowers the long-term growth algorithm.
• Evidence of structural share loss or pricing-power erosion in the core franchise.
• Unexpected rise in leverage that impairs financial flexibility.
• Governance or accounting issues that call integrity into question.
• A regulatory or technological development that removes the original competitive advantage.

Conversely, sustained acceleration in free-cash-flow, expanding margins alongside growth, or strengthening competitive position are green flags that can support higher Confidence or the willingness to hold through temporary price weakness.

Equities remain the primary long-term wealth-creation vehicle for patient investors who combine quality selection with disciplined ownership.

Final Synthesis of the Framework

The process followed across this eight-part series can be summarized in six steps that any investor can adapt:

1. Screen for quality. Begin with multi-source consensus (CFRA, Argus, LSEG, Morningstar, Schwab Equity Ratings), Economic Moat assessments, and basic financial-health filters.
2. Score multi-dimensionally. Evaluate Confidence, Value, Safety, and Timing separately so that no single factor dominates the decision.
3. Demand diversification. Explicitly limit concentration in any one sector, factor, or thematic cluster (especially AI infrastructure and large-platform technology).
4. Size for risk contribution. Higher-beta and higher-valuation names receive smaller initial weights; lower-beta compounders can be sized more meaningfully.
5. Pre-define risk responses. Establish invalidation criteria and rebalancing rules before stress arrives so that decisions are process-driven rather than emotional.
6. Monitor with cadence and focus. Quarterly fundamentals, semi-annual construction checks, and annual thesis refreshes keep the portfolio alive without requiring daily attention.

The 20 stocks selected—Microsoft, NVIDIA, Apple, Meta, Visa, Mastercard, Amazon, Alphabet, Eli Lilly, Broadcom, JPMorgan, Costco, Merck, Arista, ASML, Caterpillar, Eaton, Charles Schwab, Allstate, and T-Mobile—represent a deliberate balance of durable compounders, secular growth engines, and diversifying real-economy and financial exposures. None is perfect; each carries identifiable risks. Collectively, however, they embody the original objective: higher-quality businesses, reasonable (or at least justifiable) valuations relative to growth, acceptable risk profiles, and enough category diversification to weather different market regimes.

Data gaps in the original Schwab CSV (missing Sharpe ratios, incomplete long-term growth estimates for a few names, limited Morningstar risk statistics) were acknowledged throughout and handled by leaning more heavily on the metrics that were present. Scores remain judgment-based assessments grounded in those numbers, not algorithmic outputs.

The most important ongoing work is not finding the next new name. It is protecting the integrity of the process: maintaining quality standards, respecting position-size and sector limits, rebalancing with discipline, and exiting only when the fundamental thesis is broken. Markets will deliver volatility. A well-constructed portfolio of high-conviction businesses, monitored with clear criteria, is designed to compound through that volatility rather than be derailed by it.

Final Disclaimer: This entire eight-part series is for educational and informational purposes only. It does not constitute personalized investment advice, a recommendation to buy or sell any security, or an offer of advisory services. All investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The analysis relies on the provided Schwab stock-screen CSV data and is subject to the gaps and limitations noted throughout. Readers must conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. The author assumes no responsibility for actions taken based on this material.

Thank you for following the series from screen to synthesis. The real work now belongs to the patient, process-driven investor.

— End of Series —